Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
U.S. says Chinese stainless steel sheet, strip imports being dumped in U.S.
https://seekingalpha.com/news/3208231?source=ansh … $AKS, $ATI, $X, $MT, $NUE, $CLF, $STLD
Why Cuts in China’s Steel Exports Don’t Mean Much for US Steel
http://marketrealist.com/2016/09/cuts-chinas-steel-exports-dont-mean-much-us-steel/?utm_source=zacks-headline&utm_medium=feed&utm_content=main_permalink&utm_campaign=cuts-chinas-steel-exports-dont-mean-much-us-steel
Do not read trash
Ratings Breakdown: 5 Sell Ratings, 11 Hold Ratings, 5 Buy Ratings
Consensus Rating: Hold (Score: 2.00)
Consensus Price Target: $19.97 (4.23% upside)
8/30/2016 Axiom Securities
Reiterated Rating Sell
+8/22/2016 Citigroup Inc.
Initiated Coverage Buy $27.00
+8/19/2016 KeyCorp
Downgrade Sector Weight -> Underweight $21.81 -> $18.00
+8/16/2016 JPMorgan Chase & Co.
Reiterated Rating Overweight $37.00
+8/15/2016 Rosenblatt Securities
Lower Price Target Buy $35.00 -> $32.00
+8/3/2016 Jefferies Group
Upgrade Underperform -> Hold $24.50
+8/3/2016 Barclays PLC
Boost Price Target Equal Weight $16.00 -> $22.00
+8/2/2016 Clarkson Capital
Upgrade Sell -> Neutral
+7/28/2016 Morgan Stanley
Reiterated Rating Hold $19.00
+7/28/2016 Credit Agricole SA
Reiterated Rating Sell $10.00 -> $17.00
+7/28/2016 Argus
Upgrade Hold -> Buy $25.49 -> $30.00
+7/28/2016 Bank of America Corp.
Downgrade Neutral -> Underperform $21.00
+7/27/2016 Credit Suisse Group AG
Set Price Target Buy $29.00
+7/6/2016 Deutsche Bank AG
Upgrade Sell -> Hold $8.00 -> $15.00
+4/28/2016 Macquarie
Downgrade Neutral -> Underperform
+4/28/2016 Cowen and Company
Reiterated Rating Market Perform $8.00 -> $18.00
+4/27/2016 BMO Capital Markets
Reiterated Rating Hold
+3/20/2016 Standpoint Research
Reiterated Rating Hold
+3/9/2016 Northland Securities
Boost Price Target Neutral $8.00 -> $11.00
+3/9/2016 Nomura
Lower Price Target Neutral $11.00 -> $8.00
+9/9/2015 BB&T Corp.
Initiated Coverage Hold
+4/2/2015 Wolfe Research
Initiated Coverage Underperform
+1/23/2015 Goldman Sachs Group Inc.
Downgrade Buy -> Neutral $52.00 -> $23.00
https://www.marketbeat.com/stocks/NYSE/X
Apple, Eli Lilly, U.S. Steel: Fast Money Picks For September 7
6:27 am ET September 7, 2016 (Benzinga) Print
On CNBC's Fast Money Final Trade, Pete Najarian said that Eli Lilly and Co (NYSE: LLY) is going higher.
Tim Seymour wants to buy United States Steel Corporation (NYSE: X).
Dan Nathan is not a buyer of Apple Inc. (NASDAQ: AAPL).
Guy Adami thinks that Silver Wheaton Corp. (USA) (NYSE: SLW) should be bought.
X: 8/16/2016 JPMorgan Chase & Co. Coverage Reiterated Rating Overweight $37.00 8/22/2016
8/22/2016 Citigroup Initiated Coverage Buy $27.00
Barclays Remains Positive On Cerulean Pharma Despite Failed Renal Cancer Trial
http://www.benzinga.com/analyst-ratings/analyst-color/16/08/8406402/barclays-remains-positive-on-cerulean-pharma-despite-fai#/null
(CERU) Rating Reiterated by Canaccord Genuity, PT:$20.00 FROM $29.00
Something we do not know? ;)
http://www.americanbankingnews.com/2016/08/21/cerulean-pharma-inc-ceru-rating-reiterated-by-canaccord-genuity/
Ratings Breakdown: 3 Hold Ratings, 5 Buy Ratings
Consensus Rating: Buy (Score: 2.63)
Consensus Price Target: $9.00 (710.81% upside)
https://www.marketbeat.com/stocks/NASDAQ/CERU/
Good luck !??
You're an investor or a fan of the company. When a share is shorted, overbought field, you can not keep buying. You have to find your balance, for to rise again in an orderly manner.
http://stockcharts.com/h-sc/ui?s=AMD&p=D&yr=0&mn=3&dy=0&id=p61829176931
http://stockcharts.com/freecharts/gallery.html?s=AMD
http://stockcharts.com/h-sc/ui?s=AMD&p=D&yr=0&mn=6&dy=0&id=p77526793722
I'm an investor, not a fans. Here one comes to making money, sometimes you lose, and win. So is this business! ;)
(AMD) Downgraded to Strong Sell at Vetr Inc. $6.54 price objective
Posted by Trent Williams on Aug 23rd, 2016 //
Vetr cut shares of Advanced Micro Devices Inc. (NASDAQ:AMD) from a sell rating to a strong sell rating in a report published on Monday morning. The brokerage currently has $6.54 price objective on the semiconductor manufacturer’s stock.
AMD has been the subject of several other research reports. MKM Partners restated a buy rating and issued a $5.00 price target (up previously from $4.00) on shares of Advanced Micro Devices in a report on Monday, June 13th. Jefferies Group restated a buy rating and issued a $6.75 price target (up previously from $5.50) on shares of Advanced Micro Devices in a report on Friday, July 22nd. BMO Capital Markets restated a hold rating on shares of Advanced Micro Devices in a report on Sunday, July 10th. Sanford C. Bernstein cut Advanced Micro Devices from a market perform rating to an underperform rating and set a $3.00 price target for the company. in a report on Friday, July 8th. Finally, Credit Suisse Group AG lifted their price target on Advanced Micro Devices from $3.50 to $5.50 and gave the company an underperform rating in a report on Friday, July 22nd. Seven research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus target price of $4.39.
In other Advanced Micro Devices news, CAO Darla M. Smith sold 10,338 shares of the company’s stock in a transaction that occurred on Thursday, June 2nd. The stock was sold at an average price of $4.23, for a total value of $43,729.74. Following the transaction, the chief accounting officer now directly owns 5,608 shares of the company’s stock, valued at approximately $23,721.84. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.
Other large investors have recently modified their holdings of the company. Investors Asset Management of Georgia Inc. GA ADV increased its stake in shares of Advanced Micro Devices by 6.7% in the second quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 71,900 shares of the semiconductor manufacturer’s stock worth $370,000 after buying an additional 4,500 shares during the period. Arizona State Retirement System increased its stake in shares of Advanced Micro Devices by 4.1% in the first quarter. Arizona State Retirement System now owns 326,833 shares of the semiconductor manufacturer’s stock worth $931,000 after buying an additional 12,800 shares during the period. LS Investment Advisors LLC increased its stake in shares of Advanced Micro Devices by 71.6% in the second quarter. LS Investment Advisors LLC now owns 38,436 shares of the semiconductor manufacturer’s stock worth $198,000 after buying an additional 16,038 shares during the period. BlackRock Inc. increased its stake in shares of Advanced Micro Devices by 7.1% in the first quarter. BlackRock Inc. now owns 271,804 shares of the semiconductor manufacturer’s stock worth $774,000 after buying an additional 17,962 shares during the period. Finally, Mutual of America Capital Management LLC increased its stake in shares of Advanced Micro Devices by 4.3% in the fourth quarter. Mutual of America Capital Management LLC now owns 440,859 shares of the semiconductor manufacturer’s stock worth $1,265,000 after buying an additional 18,268 shares during the period.
Shares of Advanced Micro Devices (NASDAQ:AMD) opened at 7.58 on Monday. The stock’s 50 day moving average is $6.15 and its 200 day moving average is $4.04. Advanced Micro Devices has a 12 month low of $1.65 and a 12 month high of $8.00. The firm’s market cap is $6.03 billion.
Advanced Micro Devices (NASDAQ:AMD) last posted its quarterly earnings data on Thursday, July 21st. The semiconductor manufacturer reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. The company had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $951.89 million. On average, analysts anticipate that Advanced Micro Devices will post ($0.21) earnings per share for the current fiscal year.
Advanced Micro Devices, Inc is a global semiconductor company. The Company is engaged in offering x86 microprocessors, as a standalone central processing unit (CPU) or as incorporated into an accelerated processing unit (APU), chipsets, and discrete graphics processing units (GPUs) for the consumer, commercial and professional graphics markets, and server and embedded CPUs, GPUs and APUs, and semi-custom System-on-Chip (SoC) products and technology for game consoles.
To view Vetr’s full report, visit Vetr’s official website.
IBM, AMD and Others Plan Assault on Intel's Chip Dominance
4:01 pm ET August 23, 2016 (Dow Jones)
By Don Clark
Few companies enjoy the kind of dominance Intel Corp. does in chips for the computers found in data centers. But competitors keep trying to pry open its server stronghold, with International Business Machines Corp. the latest to brandish a new tool.
IBM, at a Silicon Valley technical conference on Tuesday, plans to reveal new details of Power9, the next addition to the line of microprocessors the technology giant uses in its own servers and -- in a recent strategy shift -- offers to other hardware companies.
Advanced Micro Devices Inc., meanwhile, is using the same event to discuss the inner workings of processor technology called Zen that it plans to use in chips targeting servers and other hardware. AMD, which uses the same x86 design as Intel, last week at a company event demonstrated a chip using Zen processor cores outpacing its larger rival's chips in one speed test.
"We had let our performance slip versus the competition," said Mark Papermaster, AMD's senior vice president and chief technology officer. "This really is quite a statement to the industry that AMD is back in high-performance processors."
ARM Holdings PLC, which licenses chip technology used in most mobile phones, is also discussing plans at the Hot Chips conference to add features for use in supercomputers and other scientific applications. The British company estimates that 13 companies already are using its technology in chips for servers and other data-center hardware, which are expected to compete with Intel products.
Of 9.81 million servers shipped last year, x86 chips were used in 9.6 million of them -- a 98% share, International Data Corp. estimates. Intel in the second quarter accounted for 99.7% of x86 server-chip shipments to just 0.3% for AMD, according to Mercury Research.
Server chips command much higher prices and profit margins than Intel's other products. The company's data center group in 2015 posted $7.8 billion in operating profit on revenue of nearly $16 billion -- a margin of 49%, compared to just under 30% for the unit that sells chips for PCs.
"There is an awful lot of margin going to Intel," said Matthew Eastwood, an IDC analyst. "Customers want alternate suppliers."
That's particularly true of large Web services such as Google Inc. and Facebook Inc., major Intel customers that nonetheless have encouraged other suppliers. Google, for instance, was one of the original members of OpenPower.org, a group IBM helped establish in 2013 to promote use of its chip technology by other companies.
Big Blue hopes to accelerate that push with Power9, which comes in two basic designs. One chip, with 24 processor cores, is targeted for Web-type companies that break up jobs to be handled by hundreds or thousands of machines. Another, with 12 cores, is aimed a larger systems designed for running applications like corporate databases.
IBM and others are partly motivated by the increasing popularity of deep learning, a trend helping to fuel sales of servers and server chips lately. The technique, a branch of a broader field called artificial intelligence, allows computers to handle tasks such as recognizing faces and speech by analyzing vast troves of data rather than explicitly programming them to do so.
The Power9 chips, expected to begin arriving in the second half of 2017, have communication links that are especially designed to exchange data with graphics processing units sold by Nvidia Corp. That company's chips are now used mainly with Intel processors for deep-learning applications.
"The hot space is on these workloads," said Brad McCredie, chief technology officer for IBM's Power line who also holds the title of fellow.
The point hasn't been lost on Intel, which has moved to add technology to satisfy server buyers. It paid $16.7 billion last year for Altera Corp., whose programmable chips can be used alongside Intel processors to accelerate particular computing chores.
Intel earlier this month purchased Nervana Systems Inc., a startup making artificial-intelligence chips and software. It also used an annual developer conference last week to discuss plans to use an existing chip line called Xeon Phi for deep-learning applications.
"We take all competition very seriously," said an Intel spokesman on Monday.
AMD expects to deliver a 32-core server chip based on its Zen technology in the second quarter of 2017. Lisa Su, its chief executive, estimated the company had spent nearly four years and hundreds of millions of dollars on the development effort.
Analysts said the company still has to prove the final product can perform in the field as well as in tests, but initial results seem promising.
"They don't have to be faster than Intel," said Linley Gwennap, an analyst with the Linley Group. "They just have to be close enough so they can compete on price."
Write to Don Clark at Don.Clark@wsj.com
(END) Dow Jones Newswires
August 23, 2016 16:01 ET (20:01 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
You're talking about more than a year. In this business, you can not think like that. It is today and sales this year. To me, no one pays me, I'm not a fan. I´m realist.
The insults are of more, be careful!
AMD: A Rigged Test May Sell Investors, But It Won't Sell Zen
Aug. 23, 2016 12:01 PM ET Mark Hibben S.Alpha
Summary
•AMD recently announced that its new Zen Summit Ridge “outperforms” Intel's Broadwell E.
•But the test was rigged in AMD's favor by hobbling the Intel processor clock rate.
•The announcement is just another example of clever (and successful) AMD marketing.
In an event intended to divert attention from the Intel (NASDAQ:INTC) Developer Forum, AMD (NASDAQ:AMD) held a competing event, also in San Francisco, in which it claimed that its new Zen Summit Ridge "outperformed" Intel's Broadwell E. But the comparison was rigged by artificially limiting the clock rate of Broadwell E. No reputable review site would engage in such a subterfuge. More to the point, no one will base a buying decision on such a comparison. Except for the AMD fans, of course.
Source: AMD
An Accomplishment Marred
Let me first say that I do agree that Summit Ridge is a significant technical accomplishment. Through the leadership of Mark Papermaster, AMD has finally managed to live up to a marketing promise for its products. At its 2015 Investor Day, Papermaster promised to deliver a 40% improvement in "instructions per cycle" (IPC), and Summit Ridge has delivered.
For purposes of highlighting the IPC improvement, the throttling the clock of Broadwell E to 3 MHz, the same as Summit Ridge, was perhaps sensible. However, AMD's handling of this in its press release was deliberately misleading:
“
During the event, AMD demonstrated an 8-core, 16-thread "Summit Ridge" desktop processor (featuring AMD's "Zen" core) outperforming a similarly configured 8-core, 16-thread Intel "Broadwell-E" processor when running the multi-threaded Blender rendering software with both CPUs set to the same clock speed.
SA contributor Paulo Santos was quite right to express reservations about this approach, since it amounted to hobbling Broadwell E. The only 8 core processor in the Broadwell E line is the 6900K, which has a base CPU clock of 3.2 GHz and a turbo clock of 3.7 GHz, as described in Anandtech's review of Broadwell E.
So, depending on how AMD set up the clocks in Broadwell E, peak performance could have been reduced by as much as 19%. While it's commendable that AMD achieved its promised 40% gain in IPC, maximum clock rate is important in overall processor performance. Any processor design trades maximum clock rate against a certain amount of parallelism, but in the end, it's net performance that counts.
And in the end, AMD chose not to compare true "real world" net performance, but opted for a rigged, artificial comparison that allowed it to claim that it was "outperforming" Intel. There isn't a reputable review site in the known universe that would do testing that way, or would claim that AMD was "outperforming" Intel on the basis of such a test.
When AMD's Summit Ridge actually gets into the hands of reviewers, it will be compared with Broadwell E running normally configured, and it will be compared not just in a single benchmark, but across a wide array of benchmarks that give a clearer picture of real world performance.
AMD's claim follows the same kind of obfuscation that it engaged in when it compared the Polaris RX 480 with the GTX 1080. You remember that right? AMD couldn't possibly claim that the 480 was superior to the 1080, so Raja Koduri chose to compare two 480's in CrossFire mode against a single 1080, claiming that these outperformed the single 1080 and were a better value.
Subsequently, the claim was found to be false by Mark Walton at Ars Technica, and I pointed out that due to the high power draw of the 480, using two of them in CrossFire would more or less obviate the claimed power efficiency benefit of the card.
We're seeing the same kind of obfuscation with the Zen comparison.
Management Pumping
Why engage in such shenanigans? Why not do a real world test and let the chips fall where they may? Summit Ridge is actually a considerable improvement over previous generations. While it may not come up to the performance level of Broadwell E, it could probably be priced to be competitive in the market place.
Except that the bar is always being moved higher, and Broadwell E won't be the performance standard for desktops for very long. Early next year, when AMD is just getting Summit Ridge to consumers en masse, Intel will be rolling out its 10 nm chips. As I've been saying all along, Zen won't be competing with the current generation 14 nm Intel chips. It will be competing with higher performance, completely redesigned 10 nm chips.
I believe that AMD management fully realize this, and that they're going to be disadvantaged all over again. The focus of management has become to pump up the stock in the near term. AMD CEO Lisa Su is also the largest individual shareholder, at 1.024 million shares. Large institutional investors, such as Mubadala Development Company, which owns 17.8% of AMD, also benefit from pumping up the stock. And Mubadala also owns Global Foundries outright.
The strategy of previewing products more than a year in advance of their release, which AMD did at its 2015 Investor Day, has worked brilliantly to pump up the stock. And AMD has been able to sustain and build anticipation for those products by investors and fans through events such as Capsaicin. I don't doubt that AMD will become a text book case for marketing and business classes for years to come.
At some point, AMD has to deliver on its promises. Certainly, it didn't deliver with Polaris. With Polaris, AMD completely abdicated at the high performance end of the market, and its Computer and Graphics segment lost money as a result in Q2. Meanwhile, Nvidia (NASDAQ:NVDA) posted a 25% y/y increase in GPU revenue and a huge increase in operating profit for the company.
In order to distract investors from the failure of Polaris, investors are now being tantalized with a new set of promises, this time about Zen.
Investor Takeaway
AMD fan reaction to my articles has devolved into standard boiler plate messages. Mark's wrong because the stock is up so much and continues to go up. The fans a missing a number of points.
First and foremost, I don't write about technology companies with the intention of influencing the price of the stock. Furthermore, my assessments of technical competitiveness are independent of the behavior of the stock price. While investors point to AMD's stock price for validation, I see it as meaningless, except as an indicator of how self deceived AMD investors have become.
My long term view on AMD hasn't changed. It's trying to compete in a market that is fundamentally on the decline. The x86 PC is simply on the decline. I believe that even Intel realizes this. So what real difference does it make if AMD becomes more competitive relative to Intel? It's just fighting for a larger piece of a shrinking pie.
AMD's focus is entirely on the wrong technology: x86 PCs and GPUs for x86 PCs. AMD's focus is on the wrong business model: commodity processors when the industry is shifting to custom processors produced by device makers such as Apple (NASDAQ:AAPL). The broad industry trends are all working against AMD, and I believe that AMD's management understand this.
So what's the end game for AMD's management? I think it's about cashing out with huge profits, which AMD's management and large institutional investors will certainly do, no matter what befalls the company.
But Zen is good enough to get some traction, and allow the AMD fan/investors to live a little longer on hope of a real turnaround. And I acknowledge the success that AMD's management have had in shaping public perceptions. Through clever manipulation of social media, AMD's management have manufactured the momentum play of the year. Therefore I'm changing my rating of the stock to buy, with this caveat: when you start to see a lot of insider selling, get out.
Disclosure: I am/we are long AAPL, NVDA.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
You Can't Believe AMD And Intel At The Same Time
http://seekingalpha.com/article/4001340-believe-amd-intel-time#alt1
Consensus recommendation & Forecast, F.TIME
As of Aug 19, 2016, the consensus forecast amongst 24 polled investment analysts covering Advanced Micro Devices, Inc. advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Jul 19, 2012. The previous consensus forecast advised that Advanced Micro Devices, Inc. would outperform the market.
Buy 4
Outperfor 3
Hold 10
Underperfor 4
Sell 3
The 17 analysts offering 12 month price targets for Advanced Micro Devices, Inc. have a median target of 5.50, with a high estimate of 9.00 and a low estimate of 2.50. The median estimate represents a -27.82% decrease from the last price of 7.62.
High 18.1% 9.00
Med -27.8% 5.50
Low -67.2% 2.50
http://markets.ft.com/data/equities/tearsheet/forecasts?s=AMD:NAQ
Advanced Micro Devices Inc's Biggest Mistake in 2016 So Far
http://www.fool.com/investing/2016/08/22/advanced-micro-devices-incs-biggest-mistake-in-201.aspx
Consensus Ratings for Advanced Micro Devices (NASDAQ:AMD) (?)
Ratings Breakdown: 6 Sell Ratings, 12 Hold Ratings, 6 Buy Ratings
Consensus Rating: Hold (Score: 2.00)
Consensus Price Target: $4.31 (43.49% downside
https://www.marketbeat.com/stocks/NASDAQ/AMD/
Morgan Stanley analyst Kathryn Huberty maintained a Sell rating on NetApp (NASDAQ: NTAP) today and set a price target of $24. The company’s shares closed yesterday at $28.85.
Analysts Have Conflicting Sentiments on These Technology Companies: NetApp Inc (NASDAQ: NTAP) and Cisco (NASDAQ: CSCO)
http://www.analystratings.com/2016/08/18/analysts-have-conflicting-sentiments-on-these-technology-companies-netapp-inc-nasdaq-ntap-and-cisco-nasdaq-csco/450919/
Gannett declares $0.16 dividend. Continuous auction of shares, I'm very hungry!! ;)
http://seekingalpha.com/news/3194139-gannett-declares-0_16-dividend?source=tweet … $GCI
http://stockcharts.com/h-sc/ui?s=GCI&p=D&yr=0&mn=3&dy=0&id=p61829176931
Why Gannett Co Inc (NYSE:GCI) is an Excellent Choice?
[Seeking Alpha] Gannett Co Inc (NYSE:GCI)(TREND ANALYSIS) is continuing its pursuit of the funny-named newspaper company tronc.
A buying spree has made it impossible for Gannett to buy back its own stock.
GCI’s shareholders would be better served with buybacks.
Is noted newspaper shark Gannett (NYSE:GCI) chasing tronc (NASDAQ:TRNC) too far?
Gannett’s initial $12.25 a share offer for its fellow newspaper publisher became public in April. The company raised its bid to $15 in May ($864 million including debt), saying the offer would remain on the table through August.
Stock Performance: Click here for a free comprehensive Trend Analysis Report
Gannett Co Inc (NYSE:GCI) stock is currently trading 32.16% below its 52-week-high, 5.47% above its 52-week-low. The 1-year stock price history is in the range of $11.52 – $17.91. Gannett Co Inc (GCI) has a price to earnings ratio of 13.92 versus Services sector average of 20.03. GCI stock price has underperformed the S&P 500 by 32.4%. The Newspapers Publishing company is currently valued at $1.42 billion, and its share price closed the last trading session at $12.15. The stock has a 50-day moving average of $13.26 and a 200-day moving average of $14.83.
Gannett Co Inc (GCI) current short interest stands at 7.67 million shares. It has decreased by 2% from the same period of last month. Around 8% of the company’s shares, which are float, are short sold. With a 10-days average volume of 1.2 million shares, the number of days required to cover the short positions stand at 6.4 days.
GCI is forecasted to report earnings per share of $0.16 and a revenue of $753.89 million for the 3rd Quarter of the fiscal year 2016. Gannett Co Inc (GCI) declared last quarter earnings on July 27. The Newspapers Publishing company announced last quarter earnings per share of $0.30 against a consensus Street estimate of $0.30, matching the average estimate. The company posted a revenue of $748.8 million compared to an estimation of $787.1 million.
Is this a Trading Opportunity? Click here for a free Trend Analysis Report
There are currently six analysts that cover Gannett Co Inc stock. Of those six, three have a Buy rating, three have a Hold rating. On a consensus basis this yields to an Overweight rating. The consensus target price stands at $16.
A recent analyst activity consisted of Jefferies reiterating their Hold stance on July 28. Jefferies decreased price target from $15 to $14. This corresponds to a 15.23% upside from the last closing price. On the date of report, the stock closed at $12.74.
Argus Research upgraded their Hold rating to Buy on November 5. On the date of report, the stock closed at $16.37.
Company snapshot
Gannett Co., Inc. is an international news and information company that publishes various daily newspapers in the United States and the United Kingdom, including “USA TODAY” and “USA WEEKEND,” a newspaper magazine. The Company also operates television stations in major United States markets as well as operates websites offering news, information and advertising.
http://www.streetreport.co/why-gannett-co-inc-nysegci-is-an-excellent-choice/52406/
Così, Inc. (NASDAQ:COSI) Releases 2016 P7 Comparable Restaurant Sales Report
Written by Alan Masterson / on August 4, 2016
Così, Inc. (NASDAQ:COSI) has issued on Wednesday its 2016 Period 7 comparable restaurant sales report.
Comparable Restaurant Sales for P7 and Q2
For the said period, Così had seen a 5.30% aggregate decrease from the same period in 2015. Year-over-year, sales from the company-owned units declined 7.80% while sales from the franchised units rose 0.30%.
During the previous period, comparable restaurant sales dropped 4.50% from the 2015 period 6 results.
Similarly, comparable restaurant sales during the second quarter declined 1.60% year-over-year.
Comparable sales from the 13 Hearthstone units also dipped 0.80% during the four-week period in July. If included in the system-wide performance report, sales would show a drop of 4.60% year-over-year.
Accordingly, the Hearthstone restaurants that Così acquired in April 2015 will officially be included in the system-wide comparable restaurant sales report for the 2016 Period 8, since it will mark their 15th consecutive month under the company.
Long-Term Prospects
RJ Dourney, Così CEO and President, noted that the company is constantly working on improving guest frequency and satisfaction. Dourney believes that focusing on the millennial guest segment is key to optimized traffic trends amid the ongoing challenges in the industry. In line with this, Così is better hospitality with new initiatives that are geared toward drive trial. Further details and long-term visions regarding these prospects, which include guest satisfaction, menu reduction, and digital campaign, are expected to be unveiled next week as the company issues its latest quarterly earnings report. As Dourney said, these initiatives are foreseen to benefit all of the company’s franchise and owned restaurants— they are an integral part of the strategic plans of Così for its franchising arm.
Presently, the new menu is already being used in more than 50% of the company’s restaurants. It is expected to be fully deployed by August 30, promising a faster and more efficient experience for both customers and employees. Meanwhile, the company’s overall digital campaign has already yielded encouraging results, which is why it hopes to explore its potentials further.
http://wallstreetpr.com/cosi-inc-nasdaqcosi-releases-2016-p7-comparable-restaurant-sales-report-37506
Sales pressure continues at Cosi
Aug 3 2016, 07:04 ET | By: Clark Schultz, SA News Editor
Cosi (NASDAQ:COSI) reports system-wide comparable restaurant sales decreased 5.3% during the company's Period 7 reporting time period.
Comparable sales fell 7.8% at company-owned restaurants.
"I believe management’s ongoing focus on unit-level costs since our operational ‘reboot’ in October has allowed us to avoid the unit-level margin degradation that often accompanies negative comparable sales results," says CEO RJ Dourney.
http://seekingalpha.com/news/3199123-sales-pressure-continues-cosi
It may come a surprise in Q2
Top 10 Owners of Cosi Inc
Janus Capital Management LLC 19.60% 9,405,129 4,702,565 0 0.00%
Trishield Capital Management LLC 9.29% 4,457,875 2,228,938 0 0.00%
The Vanguard Group, Inc. 2.37% 1,135,125 567,563 +1,608 +0.14%
Luther King Capital Management Co... 1.90% 910,625 455,313 0 0.00%
Diker Management LLC 0.98% 470,404 235,202 +67,476 +16.75%
Scopus Asset Management LP 0.94% 448,498 224,249 0 0.00%
First Manhattan Co. 0.80% 383,977 191,989 -8,089 -2.06%
GMT Capital Corp. 0.64% 305,676 152,838 +305,676 --
Susquehanna Financial Group LLLP 0.60% 290,001 145,001 +284 +0.10%
Mount Lucas Management LP 0.51% 245,000 122,500 -5,000 -2.00%
Top 10 Mutual Funds Holding Cosi Inc
http://money.cnn.com/quote/shareholders/shareholders.html?symb=COSI&subView=institutional
PTX: Forecasts, , Low:$3.00, Medium:$4.50, High: $6.00
http://money.cnn.com/quote/quote.html?symb=PTX
Largest Quarterly Institutional
Transactions
Latest Institutional Activity
Top 10 Owners of Pernix Therapeutics Holdings Inc
Top 10 Mutual Funds Holding Pernix Therapeutics Holdings Inc
http://money.cnn.com/quote/shareholders/shareholders.html?symb=PTX&subView=institutional
5:42 pm ET
Pernix Therapeutics: Sanjay Patel, Terence Novak and Barry Siegel Are No Longer Employed by the Company
Dow Jones
5:42 pm ET
Pernix Therapeutics Says Departures Don't Reflect Disagreements About Fincl Results or Disclosures
Dow Jones
5:42 pm ET
Pernix Therapeutics Intends to Regain Nasdaq Compliance Within Required Time Frame >PTX
Dow Jones
5:41 pm ET
*Pernix Therapeutics Names John Sedor CEO on Permanent Basis, Graham Miao as Pres, CFO
Benzinga
5:41 pm ET
Pernix Therapeutics: John Sedor Appointed CEO on a Permanent Basis >PTX
Dow Jones
5:41 pm ET
Pernix Therapeutics Names Graham Miao as President and CFO
Dow Jones
Stocks in the Spotlight: AbbVie Inc (NYSE:ABBV), Pernix Therapeutics Holdings Inc (NASDAQ:PTX)
july 22,2016
Pernix Therapeutics Holdings Inc (NASDAQ:PTX), jumped 10.47% and closed at $0.570 in the last trading session. The last trading range of the stock ranges between $0.51 and $0.58. The company’s Market capitalization is $35.53 Million with the total Outstanding Shares of 61.13 Million. Pernix Therapeutics Holdings, Inc. (PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, recently declared an program intended to optimize the Company’s resources and improve the effectiveness of its sales force. As part of this effort, Pernix has reduced its total full-time work force by about 23 percent.
“Since I took over the CEO duties at Pernix, we have been performing a thorough analysis of the specific market opportunities served by our products and how well they are addressed by our existing organizational structure,” said John Sedor, Pernix’s Chairman and Interim CEO. “As part of this analysis it became clear that there were noteworthyopportunities to optimize Pernix’s field force to more efficiently cover the most productive physicians. The actions declared recently are designed to improve productivity, instill a more results-based culture and facilitate Pernix to more effectively serve our customers,” said Mr. Sedor.
The key elements of this reorganization plan include: (1) a reduction of 54 sales positions, mainly from Pernix’s Neurology sales team; (2) prioritization and reorganization of sales territories to reduce the inefficient time that sales representatives spent driving long distances between customers; (3) improvement of the Company’s compensation plan to incentivize the field sales staff to increase the frequency of calls on the focused targets; and (4) consolidation of the Neurology and Pain sales forces under one sales administration structure to eliminate redundancies. In addition, as part of this program, Pernix is reducing its administrative staff by 6 employees.
http://stockznews.com/stocks-in-the-spotlight-abbvie-inc-nyseabbv-pernix-therapeutics-holdings-inc-nasdaqptx/
Short sellers cover to die. PTX about to erupt like a volcano!
http://stockcharts.com/h-sc/ui?s=PTX&p=D&yr=0&mn=3&dy=0&id=p61829176931
http://stockcharts.com/freecharts/gallery.html?s=PTX
Major Second Quarter Purchases for Cohen Include Tesaro, Pernix
http://www.gurufocus.com/news/429546/major-second-quarter-purchases-for-cohen-include-tesaro-pernix-
Buzzer of Healthcare Sector: Pernix Therapeutics Holdings, Inc.’s (PTX)
Pernix Therapeutics Holdings, Inc.’s (PTX) witnessed a loss of -2.69% in recent trading period with closing price of $ 0.51. The company’s last traded volume of 1.45 million shares was above it’s an average volume of 6.3 million shares.
In the trailing 12 months period, return on assets ratio of the Company was -27.80% and return on equity ratio was -217.10% while its return on investment ratio was -31.00%.
The stock as of last trading session moved 29.71% up from its 52 week low and was -91.69% behind its 52 week high.
The stock’s price switched up 1.25% 20-Days Simple Moving Average, added 3.76% from 50-Days Simple Moving Average and negatively -72.06% from 200 Days Simple Moving Average.
Pernix Therapeutics Holdings, Inc.’s (PTX) is expected to announce its next earnings on 8/4/2016 8:30:00 AM. The company has price to cash ratio of 0.94.
In the profitability analysis, net profit margin of the firm was recorded at -86.30% and operating profit margin was calculated at -60.80% while gross profit margin was measured as 70.40%. Beta factor, which measures the riskiness of the security, was registered at 1.49.
EPS growth for this year is -198.50% and EPS growth for next year is expected to reach at 164.70%. EPS growth in past five years was -55.20% while EPS growth in next five years is projected to arrive at 4.00%. Sales growth past 5 years was measured at 39.50%.
The Company has 67.88 million shares outstanding and 53.73 million shares were floated in market. The short ratio in the company’s stock is documented at 0.94 and the short float is around of 10.97%. The average true range of the stock is observed at 0.06 and the relative strength index of the stock is recorded at 50.78.
Analyst recommendation for this stock stands at 2.30. The volatility in the previous week has experienced by 13.66% and observed of 10.98% in the previous month.73.90% ownership is held by institutional investors while insiders hold ownership of 39.04%.
Liquidity ratio analysis:
In the liquidity ratio analysis; quick ratio for most recent quarter was 1.00 while current ratio for time period was 1.10. In most recent quarter, LT Debt/Equity ratio was listed at 35.36 and Total Debt/Equity ratio was noted at 35.36.
Performance history:
Looking about the past performance history, the company plunged -8.93% in past week and climbed 2.41% in one month. During the past three month period the stock dropped -42.53% and decreased -74.83% in past six month. During the twelve month it lost -90.96% and year to date performance of -82.85%.
http://www.isstories.com/buzzer-of-healthcare-sector-pernix-therapeutics-holdings-inc-s-ptx/8723898/
Eye Catching Stock: Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX)
By Tim Barnes -
Jul 18, 2016
The Company fell -10.02% and finished at $0.52. The daily volume was measured at 4.71 million shares. The 52-week high of the share price is $6.09 and the 52-week low is $0.39. The company has a market cap of $35.3 million. Its latest closing price has a distance of 4.48% from SMA20 and is 4.1 up than SMA50. The stock currently has Price to Sales (P/S) value of 0.2 where Price to Book (P/B) value stands at 3.71.PTX is currently showing ROA (Return on Assets) value of -27.8% where ROE (Return on Equity) is -217.1%.
Return on equity (ROE) measures the rate of return on the ownership interest (shareholders’ equity) of the common stock owners. It measures a firm’s efficiency at generating profits from every unit of shareholders’ equity (also known as net assets or assets minus liabilities).
PTX is currently showing 67.88 million shares outstanding as compared with the 53.73 million total shares float.
The Stock has its Beta Value of 1.49 and ATR (Average True Range) of 0.06. The Weekly and Monthly Volatility of the stock are 16.86% and 11.32% respectively. The weekly performance of the company stands at -5.13 percent while it’s 1-month and 3-month returns are 15.81 percent and -44.68 percent.
By looking at Pernix Therapeutics Holdings, Inc. (PTX) YTD (year to date) performance, the stock shows Negative value of -82.37%. If the YTD value is Negative, it means that the stock is trading poorly. If the YTD value is Positive, this means the stock is appreciating.
The High price target of the company’s Share is at $9 based on the calculations and analysis of 2 brokers. According to the analysts, the company has the Low Price target of $3 whereas, the Mean Target is estimated by the brokers is $6.
While Looking at the Earnings Estimates of the company, The Average Earnings Estimate for the Current Fiscal quarter is measured as -$0.08 by 3 analysts. They are also projecting the Low EPS estimate as -$0.1 as compared to the Higher EPS estimate of -$0.05.
Now when we talk about Revenue Estimate for the current Fiscal Quarter, Average Revenue Estimate of Pernix Therapeutics Holdings, Inc. (PTX) is projected as $40.33 Million where Low Revenue estimate and High Revenue Estimates are $35.1 Million and $45.4 Million respectively by 3 analysts.
http://www.newsoracle.com/2016/07/18/eye-catching-stock-pernix-therapeutics-holdings-inc-nasdaqptx-2/
Pernix Therapeutics Holdings Incorporated (NASDAQ:PTX) Short Interest Decreased By 7.55%
July 17, 2016
The stock of Pernix Therapeutics Holdings Incorporated (NASDAQ:PTX) registered a decrease of 7.55% in short interest. PTX’s total short interest was 8.08M shares in July as published by FINRA. Its down 7.55% from 8.74 million shares, reported previously. With 6.36 million shares average volume, it will take short sellers 1 days to cover their PTX’s short positions. The short interest to Pernix Therapeutics Holdings Incorporated’s float is 20.03%. The stock decreased 10.02% or $0.058 on July 15, hitting $0.52. About 4.85 million shares traded hands. Pernix Therapeutics Holdings Inc (NASDAQ:PTX) has declined 80.38% since December 9, 2015 and is downtrending. It has underperformed by 85.95% the S&P500.
Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company. The company has a market cap of $28.60 million. The Firm focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It currently has negative earnings. It focuses on underserved therapeutic areas, such as central nervous system , including neurology and psychiatry, as well as other specialty therapeutic areas.
The institutional sentiment decreased to 0.75 in Q1 2016. Its down 0.27, from 1.02 in 2015Q4. The ratio turned negative, as 23 funds sold all Pernix Therapeutics Holdings Inc shares owned while 25 reduced positions. 9 funds bought stakes while 27 increased positions. They now own 36.43 million shares or 10.39% less from 40.65 million shares in 2015Q4.
Venbio Select Advisor Llc holds 1.42% of its portfolio in Pernix Therapeutics Holdings Inc for 3.89 million shares. Broadfin Capital Llc owns 6.09 million shares or 0.62% of their US portfolio. Moreover, Aisling Capital Llc has 0.42% invested in the company for 2.01 million shares. The New York-based Armistice Capital Llc has invested 0.24% in the stock. Elk Creek Partners Llc, a Colorado-based fund reported 2.31 million shares.
Out of 4 analysts covering Pernix Therapeutics (NASDAQ:PTX), 2 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 50% are positive. Pernix Therapeutics has been the topic of 8 analyst reports since August 7, 2015 according to StockzIntelligence Inc
http://www.consumereagle.com/pernix-therapeutics-holdings-incorporated-nasdaqptx-short-interest-decreased-by-7-55/21656/
It seems that in anytime there is a buyer for PTX
Now you understand why Cowen has a stake of 6.09%
Point72 Asset Management LP 6.09% 3,724,344 shares
Now you understand why Cowen has a stake of 6.09% 3,724,344 shares
Reuters had reported in February that Pernix was working with Perella Weinberg to explore a sale.
Pernix in talks with creditors about debt restructuring -sources
Pernix Therapeutics Holdings Inc has started negotiations with creditors to restructure its debt, according to people familiar with the matter, in the latest sign of distress in the specialty pharmaceutical sector.
Pernix is struggling to cope with $340 million of debt after borrowing to buy a pain medication franchise called Zohydro in 2015 and the rights to migraine drug Treximet in 2014.
The Morristown, New Jersey-based company, which focuses on central nervous system medicines, is working with restructuring advisors at investment bank Perella Weinberg Partners LP to explore a solution with its creditors that would boost liquidity, the people said this week.
The sources asked not to be identified because the matter is confidential. Pernix declined to comment, while Perella Weinberg did not immediately respond to a request for comment.
Some makers of high-cost specialty drugs that treat complex conditions rely on debt-fueled acquisitions to boost revenues. Heightened political and regulatory scrutiny of drug prices has curbed their plans to hike prices.
Moody's Investors Service cited Valeant International Inc, Canadian company Concordia International Corp and Endo International Plc as examples of companies grappling with these issues.
"Because of the challenges of Valeant, this strategy is not a viable one going forward," Michael Levesque, an analyst at Moody's, said in a phone interview.
Pernix, with a market capitalization of $35 million, said last week it would make a payment on bonds due Aug. 1, and that it was in compliance with requirements set by its lenders. To cut costs, the company slashed its total full-time work force by 23 percent, it said last week.
The company's convertible notes maturing in 2021 traded at 20 cents on the dollar on Friday, according to Thomson Reuters data, signaling investor expectations that they will not be repaid in full.
Pernix said in 2015 its acquisitions would push revenue higher, estimating eventual annual sales of as much as $1 billion for Zohydro alone. But by the end of 2015, sales were about $175 million, as insurance companies pushed for higher-than-expected rebates on its drugs, some of which compete with multiple generic alternatives.
Reuters had reported in February that Pernix was working with Perella Weinberg to explore a sale.
http://www.reuters.com/article/us-pernix-restructuring-idUSKCN0ZV20A
Pernix Therapeutics Holdings (PTX): Price Target and June Short Interest Disclosure.
http://www.themarketdigest.org/201607/pernix-therapeutics-holdings-ptx-price-target-and-june-short-interest-disclosure/3103289/
Today, Zacks Upgrade from 3 HOLD green to 2 BUY Green
https://www.zacks.com/stock/quote/PTX
Pernix Therapeutics Hold.. buy rating reiterated at Brean Capital. $3.00 PT. 7/10/2016
http://www.marketbeat.com/r/670976 $PTX #PTX vía @RatingsNetwork
Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) Average Rating Recap
Todd Miller?May 13, 2016
Investors have a non-stop job of trying to stay on top of the latest sentiment on shares of Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX). Many investors are extremely interested in the views of sell-side equity analysts that regularly track the stock. Others may look to compiled crowd sourced ratings from regular investors and financial professionals who monitor the company closely. Beta Systems Research has provided crowd ratings using scorecards and open records. The goal is to help provide a more transparent look at the rating process, and to obtain a better feel for a broader view on stock sentiment. Shares of Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) have a current average rating of 4.43. This specific rating uses a scale from 1 to 5. Following this scale, a rating of 5 would indicate a Strong Buy recommendation. A rating of 1 would signify a Strong Sell. Out of the 7 total compiled ratings, 2 have given the stock a Moderate Buy rating, and 4 have marked the stock as a Strong Buy.
Opinions of covering sell-side equity analysts are also taken into consideration by many investors. These analysts often provide analysis and certain predictive data to help with company stock evaluation. Currently, sell-side analysts providing data compiled by Zacks Research have set a consensus target price of $7.5 on the stock. These target prices presently range from 5 to $10. These same analysts have also offered ratings on the stock. The current average broker rating for Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) is 2.33. This ABR is currently including 2 different ratings.
http://www.bibeypost.com/pernix-therapeutics-holdings-inc-nasdaqptx-average-rating-recap/
Opko Health Inc.(NYSE:OPK) &Pernix Therapeutics Holdings (NASDAQ:PTX) Healthcare Stocks on the Run
http://wallstrt24.com/opko-health-inc-nyseopk-pernix-therapeutics-holdings-nasdaqptx-healthcare-stocks-on-the-run/2410025/
PTX: Forecasts, Upgrade: Low: $5.00 +1,076.20% Medium:$5.50 +1,193.89%
High:$6.00 + 1,311.49%
http://money.cnn.com/quote/quote.html?symb=PTX
Top 10 Owners of Pernix Therapeutics Holdings Inc
Top 10 Mutual Funds Holding Pernix Therapeutics Holdings Inc
http://money.cnn.com/quote/shareholders/shareholders.html?symb=PTX&subView=institutional
PTX: Forecasts and Consensus recommendation ( Financial Times)
High+1,602.9 % $9.00
Med+1,035.3 % $6.00
Low+467.6 % $3.00
As of May 06, 2016, the consensus forecast amongst 6 polled investment analysts covering Pernix Therapeutics Holdings Inc advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Mar 10, 2016. The previous consensus forecast advised investors to purchase equity in Pernix Therapeutics Holdings Inc.
Buy 2
Outperform 2
Hold 2
http://markets.ft.com/research/Markets/Tearsheets/Forecasts?s=PTX:NMQ